Drugs / Nimorazole
Nimorazole
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02661152 | Sep 2016 → Dec 2023 | head and neck squamous cell carcinoma | Danish Head and Neck Cancer Group | Unknown | No outcome recorded |
| Phase 3 | NCT01950689 | Sep 2014 → Jan 2021 | head and neck squamous cell carcinoma | The Christie NHS Foundation Trust | Completed | No outcome recorded |
| Phase 3 | NCT01880359 | Jul 2014 → Sep 2019 | head and neck squamous cell carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04124198 Comparator | Mar 2019 → Dec 2025 overdue | human papilloma virus infection, oropharynx squamous cell carcinoma, virus associated tumor | Christian von Buchwald | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nimorazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01950689 ↗ |
| Known as | K-1900 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435966 ↗ |
| Known as | Naxogin | ChEMBL registry synonym — accepted as the source's own label CHEMBL435966 ↗ |
| Known as | Naxogin 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435966 ↗ |
| Known as | Nimorazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL435966 ↗ |
| Known as | NSC-107524 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435966 ↗ |
| Modality | Small molecule | “The drug nimorazole belongs to a class of chemicals known as 5-nitroimidazoles.” NCT01880359 ↗ |
| Route | Oral | “Patients will receive nimorazole (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week” NCT01880359 ↗ |